Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting

LUND, Sweden, May 21, 2024 /PRNewswire/ --. Hansa Biopharma, "Hansa" (NASDAQ: HNSA) (STOCKHOLM: HNSA), today announced data featuring imlifidase will be presented at the American Transplant Congress (ATC), the joint annual meeting of the American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (ATS). Imlifidase is Hansa's unique antibody-cleaving enzyme that specifically targets IgG and inhibits IgG-mediated immune response.¹

Søren Tulstrup, CEO and President, Hansa Biopharma, said: "ATC is a valuable opportunity for Hansa to share the latest science and data around imlifidase and its role in enabling transplantation for those patients who are highly sensitized. We are excited to attend ATC and showcase the progress we are making across our Transplantation therapy area and these data underscore our continued commitment to advancing innovative new approaches to transplantation care."

Imlifidase has conditional marketing approval in Europe under the trade name IDEFIRIX for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. The Company is conducting an open label, randomized controlled Phase 3 trial in the US in kidney transplantation and plans to submit a Biologic License Application (BLA) to the US Food and Drug Administration (FDA) in 2025. The molecule is also being studied as a pre-treatment to gene therapy in rare disease patients with pre-existing antibodies and in autoimmune conditions including anti-GBM and Guillain Barre Syndrome (GBS).

Key abstracts at ATC include:

Abstract Title and Location	Presentation Details
Reestablishment of COVID-Specific IgG Antibodies After Imlifidase Treatment                                      Abstract B058                                     Poster Hall‚ Exhibit Hall A‚ Level 2